Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ozagrel

Next Previous
Drug Profile

Ozagrel

Alternative Names: Cataclot; Domenan; KCT-0809; OKY 046; OXY-046 HCl; Vega; Xanbon

Latest Information Update: 24 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kissei Pharmaceutical; Ono Pharmaceutical
  • Developer Kissei Pharmaceutical; Teika Pharmaceutical
  • Class Antiasthmatics; Antihistamines; Antithrombotics; Methacrylates; Small molecules
  • Mechanism of Action Thromboxane A2 receptor antagonists; Thromboxane A2 synthase inhibitors; Thromboxane synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Asthma; Cerebral vasospasm; Diabetic nephropathies; Intracranial thrombosis
  • Discontinued Cerebral infarction; Cough; Dry eyes; Glomerulonephritis; Hypertension in pregnancy; Myocardial infarction; Transplant rejection

Most Recent Events

  • 26 May 2017 Kissei Pharmaceutical completes a phase III trial in Dry eyes (associated with Sjögren's Syndrome) in Japan (Ophthalmic) (NCT02503189)
  • 24 Apr 2017 Kissei Pharmaceutical terminates a phase III extension trial for Dry eyes in Japan since the results of the Phase III clinical study conducted in Japan failed to demonstrate the expected efficacy of this drug (Opthalmic) (NCT02503163)
  • 24 Apr 2017 Kissei Pharmaceutical terminates a phase III extension trial for Dry eyes in Japan since the results of the Phase III clinical study conducted in Japan failed to demonstrate the expected efficacy of this drug (Opthalmic) (NCT02503176)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top